Advanced search
Publication Cover
Biologics: Targets and Therapy Volume 17, 2023 - Issue
Submit an article Journal homepage
159
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Treatment Persistence of Apremilast Among Patients with Psoriatic Arthritis

Amir Haddad1 Rheumatology Unit, Carmel Medical Center, Haifa, IsraelCorrespondence[email protected] [email protected]
View further author information
,
Nili Stein2 Department of Epidemiology, Clalit Health Services, Haifa, IsraelView further author information
,
Idit Lavi2 Department of Epidemiology, Clalit Health Services, Haifa, IsraelView further author information
,
Lisa Shynkar3 Internal Medicine Department, Carmel Medical Centre, Haifa, IsraelView further author information
,
Irina Bergman3 Internal Medicine Department, Carmel Medical Centre, Haifa, Israel;4 Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, IsraelView further author information
,
Ilan Feldhamer5 Chief Physician’s Office, Central Headquarters, Clalit Health Services, Tel Aviv, IsraelView further author information
,
Arnon Dov Cohen5 Chief Physician’s Office, Central Headquarters, Clalit Health Services, Tel Aviv, Israel;6 Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheba, IsraelView further author information
,
Walid Saliba2 Department of Epidemiology, Clalit Health Services, Haifa, Israel;4 Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, IsraelView further author information
&
Devy Zisman1 Rheumatology Unit, Carmel Medical Center, Haifa, Israel;4 Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, IsraelView further author information
 show all
Pages 129-136 | Received 04 Jul 2023, Accepted 27 Sep 2023, Published online: 04 Oct 2023

References

  • Otezla (apremilast) [package insert]. Summit: Celgene Corporation; 2019. Available from: https://media2.celgene.com/content/uploads/otezla-pi.pdf. Accessed September 29, 2023.
  • Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583–1590. doi:10.1016/j.bcp.2012.01.001
  • Zerilli T, Ocheretyaner E. Apremilast (Otezla): a new oral treatment for adults with psoriasis and psoriatic arthritis. P T. 2015;40(8):495–500. doi:10.1186/1477-7525-11-82
  • Coates LC, FitzGerald O, at Al HPS. Psoriasis, psoriatic arthritis, and rheumatoid arthritis: is all inflammation the same? Semin Arthritis Rheum. Seminars in Arthritis and Rheumatism. 2016;46:291–304. doi:10.1016/j.semarthrit.2016.05.012
  • Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomized, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020–1026. doi:10.1136/annrheumdis-2013-205056
  • Cutolo M, Myerson GE, Fleischmann R, et al. A Phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. J Rheumatol. 2016;43(9):1724–1734. doi:10.3899/jrheum.151376
  • Vinker S, Fogelman Y, Elhayany A, et al. Usefulness of electronic databases for the detection of unrecognized diabetic patients. Cardiovasc Diabetol. 2003;2(1):13. doi:10.1186/1475-2840-2-13
  • Eder L, Cohen AD, Feldhamer I, et al. The epidemiology of psoriatic arthritis in Israel - a population-based study. Arthritis Res Ther. 2018;20(1):3. doi:10.1186/s13075-017-1497-4
  • Filc D, Davidovich N, Novack L, et al. Is socioeconomic status associated with utilization of health care services in a single-payer universal health care system? Int J Equity Health. 2014;13(1):115. doi:10.1186/s12939-014-0115-1
  • Graier T, Weger W, Sator PG, et al. Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: a registry analysis. JAAD Int. 2021;2:62–75. doi:10.1016/j.jdin.2020.10.012
  • Del Alcazar E, Suarez-Perez JA, Armesto S, et al. Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicenter study by the Spanish Psoriasis Group. J Eur Acad Dermatol Venereol. 2020;34(12):2821–2829. doi:10.1111/jdv.16439
  • Kishimoto M, Komine M, Kamiya K, et al. Drug survival of apremilast in a real-world setting. J Dermatol. 2019;46(7):615–617. doi:10.1111/1346-8138
  • Sbidian E, Billionnet C, Weill A, et al. Persistence of apremilast in moderate-to-severe psoriasis: a real-world analysis of 14147 apremilast- and methotrexate-naive patients in the French National Health Insurance database. Br J Dermatol. 2020;182(3):690–697. doi:10.1111/bjd.18047
  • Lunder T, Zorko MS, Kolar NK, et al. Drug survival of biological therapy is showing class effect: updated results from Slovenian National Registry of psoriasis. Int J Dermatol. 2019;58(6):631–641. doi:10.1111/ijd.14429
  • Wu B, Muser E, Teeple A, et al. Treatment adherence and persistence of five commonly prescribed medications for moderate to severe psoriasis in a U.S. commercially insured population. J Dermatolog Treat. 2020:1–8. doi:10.1080/09546634.2019.1687828
  • Koskivirta I, Ruotsalainen J, Kurki S, et al. A Real-world registry-based study on apremilast use in psoriasis and psoriatic arthritis in Finland. Scand J Rheumatol. 2023;16:1–7. doi:10.1080/03009742.2022.2151109
  • Favalli EG, Conti F, Selmi C, et al. Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients. Clin Exp Rheumatol. 2020;38(1):19–26.
  • Sfikakis PP, Vassilopoulos D, Katsifis G, et al. Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study. Rheumatol Int. 2023;43(5):889–902. doi:10.1007/s00296-022-05269-z
  • Foti R, Visalli E, Amato G, et al. Drug Survival of Apremilast for Psoriatic Arthritis in a Real-World Setting: a Single-Center Experience. J Rheumatol. 2023;50(3):458–459. doi:10.3899/jrheum.220333
  • Feldman SR, Pelletier CL, Wilson KL, et al. Treatment patterns and costs among biologic-naive patients initiating apremilast or biologics for psoriatic arthritis. J Comp Eff Res. 2019;8(9):699–709. doi:10.2217/cer-2019-0034
  • Haddad A, Gazitt T, Feldhamer I, et al. Treatment persistence of biologics among patients with psoriatic arthritis. Arthritis Res Ther. 2021;23(1):44. doi:10.1186/s13075-021-02417-x

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.